Panacos Pharmaceuticals (PANC) Reports a Q4 Loss of 17c
More News related to PANC
- Panacos Pharmaceuticals (PANC) Hires Oppenheimer & Co. to Review Strategic Alternatives; Reduces Workforce
- Panacos Pharmaceuticals (PANC) Reports Q3 Loss of $0.15, Beats by 5c
- Panacos Pharmaceuticals, Inc. (PANC) Reports Q3 In-Line
- Pre-Open Movers 6/18: Lindsay Corp (LNN) Lower After Results, Fifth Third (FITB) Sinks on Capital Raise/Div Cut/Revised Capital Ratio
- Panacos Pharmaceuticals (PANC) Reports Q1 Loss of $0.16, Tops Street By 3c
More News related to Earnings
- Grubb & Ellis (GBE) Posts Q3 Loss of $0.33, Tops Y/Y; Revs Beat Estimates
- PHC (PHC) Posts Q1 EPS of 1c, Better Y/Y
- Atrinsic (ATRN) Posts Q3 Loss of $0.12, Tops Y/Y
- Macy's (M) Reports Better-Than-Expected Q3 Loss of $0.03; Raises Q4 Outlook Below the Street
- ZIOPHARM Oncology (ZIOP) Posts Q3 Loss of $0.13, Better Y/Y
Panacos Pharmaceuticals (Nasdaq: PANC) reports a Q4 loss of $0.17, 3 cents better than the analyst estimate of ($0.20). Revenues for the quarter were $22k, versus the consensus of $30k.
Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat Human Immunodeficiency Virus (HIV) and other human viral diseases.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
